Back

Clinical Trials

Share this article

There are a number of databases that can be searched for clinical trials both past and present.  Trials can be recruiting internationally and can take place in many countries to recruit patients more quickly. This is particularly important for rare cancers.

Cancer Research UK has a database of trials in the UK.  

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.

Geographically specific databases:

The Adenoid Cystic Carcinoma Research Foundation ('ACCRF') has compiled a list of clinical trials for ACC patients with progressive disease to consider. This website is updated periodically, but may not list all the pertinent and available trials. 

 

Update on trials in the UK - July 2026

CRUK DETERMINE Trial has 6 Slots Remaining for HER2-positive SGC patients on the CRUK DETERMINE Trial Arm 04 evaluating trastuzumab and pertuzumab.

The ongoing CRUK DETERMINE Trial. DETERMINE is an umbrella-basket platform trial to evaluate licensed targeted therapies in unlicensed indications, in rare adult, paediatric, and teenage/young adult cancers with actionable genomic alterations (including common cancers with rare actionable alterations).

DETERMINE Treatment Arm 04 is evaluating trastuzumab and pertuzumab for adult, paediatric, and teenage/young adult participants with HER2-positive malignancies. Within the Treatment Arm, there is a cohort for eligible participants with eligible patients with salivary gland cancer and ERBB2/HER2 amplification or insertion/indels.

There are currently six “slots” remaining in this cohort.

The trial is actively seeking salivary gland cancer patients with HER2-positivity (ERBB2/HER2 amplification or insertion/indels).

This is found more commonly in Salivary Duct Carcinoma and Adenocarcinoma NOS (Not Otherwise Specified) but is also found in many others. The DETERMINE trial is open to all types of salivary gland cancer patients - it's the HER2-positivity that is key to taking part.

Find Out More & Share: Please share this information widely within clinical and patient networks. Recruitment is expected to continue until 2027.

DETERMINE For Patients: https://lnkd.in/eXuydBU8
In addition to the salivary gland cohort above, the DETERMINE team would also like to raise awareness of the following DETERMINE cohorts:
  • HER2-positive Solid Tumour Cohort - Treatment Arm 04 – Trastuzumab + Pertuzumab
    Eligible patients:  Any solid tumour with ERBB2/HER2 amplification or ERBB2/HER2 insertion/indel alterations
    Exclusions:  Colorectal cancer (CRC) and Lung cancer
  • BRAF V600E Ultra-Rare Cohort - Treatment Arm 07 – Dabrafenib + Trametinib
    Eligible patients: Solid tumours harbouring a BRAF V600E mutation
    Exclusions:  Melanoma / NSCLC / Anaplastic thyroid cancer / Glioma / Biliary tract cancer / Colorectal cancer (CRC) / Differentiated thyroid cancer

Join the trial PRONTO!

We are excited to announce that the pivotal PRONTO trial is officially open for recruitment at The Christie and UCLH, representing a significant step forward in optimising care for Salivary Gland Cancer.

PRONTO is an evaluative study investigating the role of Proton Beam Radiotherapy (PBT) as an adjuvant treatment for patients with localised parotid carcinoma, the most common site for SGC.

Crucially, the primary focus of this study is on patient quality of life: specifically, evaluating whether PBT can significantly reduce the incidence of long-term taste disturbance compared to conventional X-ray radiotherapy.

Any radiotherapy department in England and Wales can now refer eligible patients via the NHS Proton Referral Portal, and we encourage both patients and clinicians to learn more about this vital research aimed at improving survivorship.

AL101 Trial targeting NOTCH pathway activation at the Christie Hospital in Manchester - now closed

This trial opened in Dec 2019 and is now closed.